lp-a.org

Video

AHA 2026: Lp(a)HORIZON, does lowering Lp(a) reduce cardiovascular risk? (Steven Nissen with Harriette Van Spall)

Steven Nissen, Harriette Van Spall · · 16:11

Steven Nissen (Cleveland Clinic), senior author of Lp(a)HORIZON, discusses the primary results and the extended analyses with Harriette Van Spall (McMaster University). The first cardiovascular outcomes trial of a targeted Lp(a)-lowering therapy randomised 8,322 patients with established cardiovascular disease and Lp(a) of 70 mg/dL or more to monthly subcutaneous pelacarsen 80 mg or placebo. Lp(a) fell 78 percent, yet over a median 4.7 years the primary endpoint of cardiovascular death, myocardial infarction, stroke or urgent coronary revascularisation occurred in 12.3 versus 12.1 percent (hazard ratio 1.02, 95 percent CI 0.90 to 1.15), with no effect above 90 mg/dL or in any subgroup. Why a neutral result after such a large reduction, what it means for olpasiran and lepodisiran, and why measuring Lp(a) still matters. Presented in LBS.01 on 7 November 2026 and published simultaneously in NEJM and NEJM Evidence. Recorded at AHA Scientific Sessions 2026 by Radcliffe Cardiology.

Watch at the source

aha 2026lpa horizonoutcomes trialpelacarsenphase 3RNA therapeuticssecondary prevention

Player and playback by Radcliffe Cardiology; the framing above is lp-a.org's. Page updated 10 November 2026.